Condensed Consolidated Statement of Stockholders’ Deficit (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended	9 Months Ended	12 Months Ended			39 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2013	Sep. 30, 2013
Changes during the period from incorporation
Loss for the period	$ 1,598	$ (2,316)	$ (12,575)	$ (2,117)	$ (895)	$ (17,904)	$ (17,904)
Balance	7,825	7,825	14	3,196	(505)	7,825	7,825
Warrant amendment expense		734
Issuable amount of ordinary shares in connection with anti-dilution provisions				80
Share-based compensation		2,203	4,512				6,716
Founder Shares [Member] | Founder Shares [Member]
Changes during the period from incorporation
Conversion of Ordinary Shares			110
Conversion of Ordinary Shares (in Shares)			4,500,000
Founder Shares [Member]
Changes during the period from incorporation
Balance			110
Balance (in Shares)			4,500,000
Reverse merger acquisition		(168)
Reverse merger acquisition (in Shares)		(6,750,000)
Series A Preferred Stock [Member] | Series A Preferred Stock [Member]
Changes during the period from incorporation
Conversion of Ordinary Shares			71
Conversion of Ordinary Shares (in Shares)			2,529,685
Series A Preferred Stock [Member]
Changes during the period from incorporation
Balance			71
Balance (in Shares)			2,529,685
Reverse merger acquisition		(71)
Reverse merger acquisition (in Shares)		(2,529,685)
Ordinary Shares [Member] | Series A Preferred Stock [Member]
Changes during the period from incorporation
Conversion of Ordinary Shares			(71)
Conversion of Ordinary Shares (in Shares)			(2,529,685)
Ordinary Shares [Member] | Founder Shares [Member]
Changes during the period from incorporation
Conversion of Ordinary Shares			(110)
Conversion of Ordinary Shares (in Shares)			(4,500,000)
Ordinary Shares [Member]
Changes during the period from incorporation
Balance			121	271	133
Balance (in Shares)			4,806,132	10,660,351	5,800,000
Deemed dividend on issuance of anti-dilution shares		13
Deemed dividend on issuance of anti-dilution shares (in Shares)		525,381
Reverse merger acquisition		(196)
Reverse merger acquisition (in Shares)		(7,687,860)
Issuable amount of ordinary shares in connection with anti-dilution provisions				5
Issuable amount of ordinary shares in connection with anti-dilution provisions (in Shares)				182,658
Common Stock [Member]
Changes during the period from incorporation
Balance	1	1				1	1
Balance (in Shares)	13,276,037	13,276,037				13,276,037	13,276,037
Reverse merger acquisition		1
Reverse merger acquisition (in Shares)		13,276,037
Additional Paid-in Capital [Member] | Founder Shares [Member]
Changes during the period from incorporation
Conversion of Ordinary Shares			2,803
Additional Paid-in Capital [Member]
Changes during the period from incorporation
Balance	26,659	26,659	15,299	5,937	257	26,659	26,659
Deemed dividend on issuance of anti-dilution shares		919
Reverse merger acquisition		434
Warrant amendment expense		734
Issuable amount of ordinary shares in connection with anti-dilution provisions				75
Share-based compensation		2,203	4,512
Retained Earnings [Member]
Changes during the period from incorporation
Loss for the period		(2,316)	(12,575)	(2,117)	(895)
Balance	(18,835)	(18,835)	(15,587)	(3,012)	(895)	(18,835)	(18,835)
Deemed dividend on issuance of anti-dilution shares		(932)
Founder Shares [Member]
Changes during the period from incorporation
Conversion of Ordinary Shares			2,803
Capitalization of Entity [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With (in Shares)					1,000,000
Contribution of Immune Corp. [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With (in Shares)					4,000,000
Issuance of Ordinary Shares in Connection With					111
Contribution of Immune Corp. [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With					(401)
Contribution of Immune Corp. [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With					(290)
Consulting Agreements [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With (in Shares)		72,917		400,000	800,000
Issuance of Ordinary Shares in Connection With		2		11	22
Consulting Agreements [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With		123		329	658
Consulting Agreements [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With		125		340	680
Intangibles [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares and Warrants in Connection With				63
Issuance of Ordinary Shares and Warrants in Connection With (in Shares)				2,200,000
Intangibles [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares and Warrants in Connection With				2,533
Intangibles [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares and Warrants in Connection With				5,296
In Connection with Investments [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares and Warrants in Connection With		50	18	51
Issuance of Ordinary Shares and Warrants in Connection With (in Shares)		1,933,417	702,273	1,814,740
In Connection with Investments [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares and Warrants in Connection With		4,318	1,220	2,425
In Connection with Investments [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares and Warrants in Connection With		4,368	1,238	2,476
Convertible Loans [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With (in Shares)			408,809	262,953
Issuance of Ordinary Shares in Connection With			12	8
Convertible Loans [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With			716	318
Convertible Loans [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With			728	326
Anti-Dilution Provisions [Member] | Ordinary Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With (in Shares)		350,013
Issuance of Ordinary Shares in Connection With		10
Issuable amount of ordinary shares in connection with anti-dilution provisions			1
Issuable amount of ordinary shares in connection with anti-dilution provisions (in Shares)			64,384
Anti-Dilution Provisions [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With		650
Issuable amount of ordinary shares in connection with anti-dilution provisions			111
Anti-Dilution Provisions [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With		660
Issuable amount of ordinary shares in connection with anti-dilution provisions			112
Founder [Member] | Founder Shares [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With (in Shares)		2,250,000
Issuance of Ordinary Shares in Connection With		58
Founder [Member] | Additional Paid-in Capital [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With		1,979
Founder [Member]
Changes during the period from incorporation
Issuance of Ordinary Shares in Connection With		$ 2,037